Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 10/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909089 | 0.92 | S1PR2 (0.78) | S1PR2AKR1B1TSHRCMA1CYP1A2 | |
| SCHEMBL23966552 | 0.88 | S1PR2 (0.84) | S1PR2AKR1B1NLRP3TSHR | |
| SCHEMBL23908861 | 0.88 | S1PR2 (0.76) | S1PR2AKR1B1TSHRCMA1CYP1A2 | |
| SCHEMBL23915343 | 0.84 | S1PR2 (0.58) | S1PR2AKR1B1 | |
| SCHEMBL23914638 | 0.83 | S1PR2 (0.80) | S1PR2TSHRCMA1 | |
| SCHEMBL23908752 | 0.83 | S1PR2 (0.65) | S1PR2AKR1B1MEN1KMT2A | |
| SCHEMBL23908858 | 0.82 | S1PR2 (0.75) | S1PR2TSHRCMA1 | |
| SCHEMBL23966848 | 0.81 | S1PR2 (0.72) | S1PR2NLRP3TSHR | |
| SCHEMBL23915473 | 0.81 | S1PR2 (0.67) | S1PR2AKR1B1TSHRCMA1 | |
| SCHEMBL23914679 | 0.81 | S1PR2 (0.56) | S1PR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885AKR1B1 124/4885NLRP3 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.